Business Context and Reporting Period
Filing: Aileron Therapeutics, Inc. Form 10-Q for the quarter ended June 30, 2023. The request identifies Rein Therapeutics, Inc., but the filing text identifies the registrant as Aileron Therapeutics, Inc. (Nasdaq: ALRN).
Aileron was a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX dual inhibitor. In February 2023, the company terminated its Phase 1b breast cancer chemoprotection trial and discontinued further development of ALRN-6924. It reduced its workforce from nine to three full-time employees and began evaluating strategic alternatives, including an acquisition, merger, business combination, asset sale, dissolution or liquidation.
Financial Condition and Key Metrics
| Metric | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 | Comparable Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $0.2 million | $2.0 million | $5.4 million and $11.3 million, respectively |
| General and administrative expense | $1.9 million | $4.1 million | $2.6 million and $5.1 million, respectively |
| Restructuring and other expense | $(0.1) million | $0.9 million | $0 |
| Total operating expenses | $2.0 million | $7.0 million | $8.0 million and $16.5 million, respectively |
| Net loss | $1.8 million | $6.6 million | $8.0 million and $16.4 million, respectively |
| Net loss per share | $0.39 | $1.45 | $1.76 and $3.62, respectively |
The company had no revenue and no meaningful operating margin because it remains pre-commercial and generated operating losses. Interest income was $0.1 million for the quarter and $0.2 million for the first six months. Other income was $0.1 million for the quarter and $0.3 million for the first six months.
- Cash and cash equivalents at June 30, 2023: $13.2 million.
- Investments at June 30, 2023: $0.5 million.
- Cash, cash equivalents and investments: $13.7 million.
- Restricted cash: $25 thousand.
- Accumulated deficit: $279.4 million.
- Total liabilities: $1.2 million; the filing reports no debt financing.
- Stockholders’ equity: $12.8 million.
- Net cash used in operating activities: $7.8 million for the first six months, compared with $13.5 million in the prior-year period.
- Net cash provided by investing activities: $15.8 million, primarily from sales or maturities of investments.
- No financing proceeds were received in either comparable six-month period.
Material Changes Versus the Prior Comparable Period
- First-half research and development expense declined by $9.3 million, primarily because of reduced trial, manufacturing and personnel costs following the discontinuation of ALRN-6924 development.
- First-half general and administrative expense declined by $1.1 million, primarily due to lower headcount costs.
- First-half total operating expenses decreased by $9.5 million, despite $0.9 million of one-time restructuring charges.
- First-half net loss improved by $9.8 million, from $16.4 million to $6.6 million.
- Operating cash burn decreased by $5.7 million year over year.
- Investments declined from $16.0 million at December 31, 2022 to $0.5 million at June 30, 2023, while cash and cash equivalents increased from $5.2 million to $13.2 million as investments matured or were sold.
- The company allowed its Boston office sublease to expire on March 31, 2023 and is operating virtually.
- The workforce reduction was completed during the second quarter; approximately $0.9 million of related severance and other costs were recorded, with remaining payments expected through the fourth quarter of 2023.
Outlook, Risks, Contingencies and Unusual Items
Management expects operating expenses and research and development spending to continue declining during the second half of 2023. However, future cash requirements depend substantially on the timing and cost of the strategic alternatives process and the company’s ability to complete a transaction.
The company explicitly concluded that there is substantial doubt about its ability to continue as a going concern for twelve months after issuance of the interim financial statements. Management states that current resources may fund operating expenses for at least twelve months under its current plan, but this expectation is subject to the uncertain timing and costs of strategic alternatives.
- No strategic transaction had been completed, and there was no set timetable or assurance that a transaction would occur or be completed on attractive terms.
- The board may pursue dissolution and liquidation. The company also stated that it may seek bankruptcy protection if it cannot complete a strategic transaction or raise additional funds.
- If liquidation or bankruptcy occurs, the amount available for stockholders could be substantially reduced or zero after payment or reservation for obligations and contingencies.
- The company does not expect product revenue because it has no product candidates under development.
- The company has approximately 646,759 common warrants outstanding with a $40.00 exercise price and 485,985 stock options outstanding at June 30, 2023; these securities were excluded from diluted loss per share as anti-dilutive.
- The equity line with Lincoln Park Capital was not available because the Nasdaq closing price was below its $6.00 floor price. No shares were sold under that arrangement or the ATM program during the first six months.
- The company reported no material legal proceedings and stated that disclosure controls and procedures were effective as of June 30, 2023.
Most Important Facts to Verify
- Confirm the registrant identity: the supplied filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Verify the company’s liquidity runway and actual cash consumption after June 30, 2023.
- Monitor whether a strategic transaction, dissolution, liquidation or bankruptcy process is announced.
- Assess the impact of terminating ALRN-6924 development and closing the breast cancer trial.
- Review remaining restructuring, trial close-out, licensing, professional fee and other contractual obligations.
- Confirm Nasdaq listing compliance and the availability of future equity financing, particularly given the LPC floor-price restriction.
- Evaluate potential dilution from outstanding warrants and stock options if the company completes a financing or strategic transaction.